Lymphoblastic leukemia, acute, with lymphomatous features
diseaseOn this page
Also known as lallleukemia, acute lymphoblastic
Summary
Lymphoblastic leukemia, acute, with lymphomatous features (MONDO:0009539) is a cancer and 20 clinical trials. Top therapeutic interventions include daunorubicin, blinatumomab, and bendamustine. A subtype of acute lymphoblastic leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 20
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | lymphoblastic leukemia, acute, with lymphomatous features |
| Mondo ID | MONDO:0009539 |
| MeSH | C565429 |
| OMIM | 247640 |
| UMLS | C1855472 |
| MedGen | 340879 |
| GARD | 0024679 |
| Is cancer (heuristic) | yes |
Also known as: lall · leukemia, acute lymphoblastic · lymphoblastic leukemia, acute, with lymphomatous features
Disease family
This is a subtype of acute lymphoblastic leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › acute lymphoblastic leukemia › lymphoblastic leukemia, acute, with lymphomatous features
Related subtypes (11): childhood acute lymphoblastic leukemia, prolymphocytic leukemia, adult acute lymphoblastic leukemia, null-cell leukemia, B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, T-cell acute lymphoblastic leukemia, plasma cell leukemia, acute biphenotypic leukemia, precursor B-cell acute lymphoblastic leukemia, precursor T-cell acute lymphoblastic leukemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 20.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 10 |
| PHASE2 | 4 |
| PHASE1/PHASE2 | 3 |
| PHASE3 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04307576 | PHASE3 | RECRUITING | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia |
| NCT02393859 | PHASE3 | COMPLETED | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) |
| NCT05306301 | PHASE2 | ACTIVE_NOT_RECRUITING | Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients |
| NCT06101381 | PHASE1/PHASE2 | RECRUITING | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma |
| NCT06364423 | PHASE1/PHASE2 | RECRUITING | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias |
| NCT02349178 | PHASE2 | TERMINATED | Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT |
| NCT02799147 | PHASE1/PHASE2 | COMPLETED | GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia |
| NCT02935543 | PHASE2 | TERMINATED | CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL |
| NCT04942730 | PHASE2 | COMPLETED | Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) |
| NCT04327037 | PHASE1 | COMPLETED | Safety of Expanded Haploidentical Natural Killer Cells for Leukemia |
| NCT03911128 | Not specified | RECRUITING | A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia |
| NCT04209244 | Not specified | RECRUITING | Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia |
| NCT06626893 | Not specified | RECRUITING | Integrative Omics Approaches for Leukemia Target Identification and Matched Therapeutic Intervention |
| NCT00590915 | Not specified | NO_LONGER_AVAILABLE | Erwinase Master Treatment Protocol |
| NCT01761682 | Not specified | TERMINATED | Acute Lymphoblastic Leukemia Registry at Asan Medical Center |
| NCT02360930 | Not specified | UNKNOWN | Vincristine PK and PD in the AYA Population Compared to Younger Children |
| NCT02435550 | Not specified | TERMINATED | iCare for Cancer Patients |
| NCT02580981 | Not specified | TERMINATED | Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses |
| NCT05064787 | Not specified | COMPLETED | Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy |
| NCT05440409 | Not specified | COMPLETED | CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DAUNORUBICIN | 4 | 3 |
| BLINATUMOMAB | 4 | 2 |
| BENDAMUSTINE | 4 | 1 |
| CLOFARABINE | 4 | 1 |
| IFOSFAMIDE | 4 | 1 |
| IMATINIB | 4 | 1 |
| INOTUZUMAB OZOGAMICIN | 4 | 1 |
| PEGASPARGASE | 4 | 1 |
| PONATINIB | 4 | 1 |
| TISAGENLECLEUCEL | 4 | 1 |
| CHEMBL1171086 | 0 | 1 |
| CHEMBL4519289 | 0 | 1 |